First Heart Attack Patient Treated in European Cardioprotection Phase III Trial with NeuroVive's CicloMulsion (TM)Investigator-initiated European multicenter trial of 1,000 acute heart attack patients will examine the ability of cyclosporine to protect cardiac tissue.
LUND, SWEDEN, April 19, 2011 /24-7PressRelease/ -- NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter
No comments:
Post a Comment